

David J Matheson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4165052/publications.pdf>

Version: 2024-02-01

18
papers

4,529
citations

687363

13
h-index

839539

18
g-index

18
all docs

18
docs citations

18
times ranked

4627
citing authors

#	ARTICLE	IF	CITATIONS
1	Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 825-836.	1.6	40
2	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. <i>Lancet, The</i> , 2022, 399, 447-460.	13.7	173
3	The role of distance and transportation in decision making to seek emergency obstetric care among women of reproductive age in southâ€”South Nigeria: A mixed methods study. <i>International Journal of Gynecology and Obstetrics</i> , 2022, 159, 263-269.	2.3	6
4	Psychosocial aspects and support networks associated with disability in two longevous populations in Brazil: a cross-sectional study. <i>BMC Geriatrics</i> , 2022, 22, 110.	2.7	3
5	Health-Related Quality of Life and Associated Factors: Regional Differences Among Oldest-Old in Brazil. <i>Inquiry (United States)</i> , 2022, 59, 004695802210869.	0.9	5
6	Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5â€”year followâ€”up results from the STAMPEDE randomised trial (NCT00268476). <i>International Journal of Cancer</i> , 2022, 151, 422-434.	5.1	29
7	Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data. <i>PLoS ONE</i> , 2022, 17, e0269192.	2.5	4
8	Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. <i>PLoS Medicine</i> , 2022, 19, e1003998.	8.4	35
9	The prevention of arboviral diseases using mobile devices: a preliminary study of the attitudes and behaviour change produced by educational interventions. <i>Tropical Medicine and International Health</i> , 2019, 24, 1411-1426.	2.3	7
10	Abiraterone in â€”Highâ€”and â€”Low-riskâ€”Metastatic Hormone-sensitive Prostate Cancer. <i>European Urology</i> , 2019, 76, 719-728.	1.9	142
11	Using co-creation as a pedagogic method for the professional development of students undertaking a BA (Hons) in Education Studies. <i>Journal of Further and Higher Education</i> , 2019, 43, 826-838.	2.5	15
12	Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. <i>European Urology Oncology</i> , 2018, 1, 449-458.	5.4	19
13	Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2018, 392, 2353-2366.	13.7	901
14	Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. <i>New England Journal of Medicine</i> , 2017, 377, 338-351.	27.0	1,315
15	Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1530-1541.	1.6	54
16	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. <i>Lancet, The</i> , 2016, 387, 1163-1177.	13.7	1,570
17	Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 348.	7.1	155
18	Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial. <i>European Urology</i> , 2014, 66, 799-802.	1.9	56